Dose-response, net clinical benefit and optimal dose ranges of stimulants in children and adolescents with ADHD: a network meta-analysis

Stimulant treatment with methylphenidate (MPH) and amphetamines (AMP) is first-line for children and adolescents with attention-deficit/hyperactivity disorder (ADHD), but quantitative guidance on comparative efficacy and dose selection within licensed dose ranges remains limited. This study aimed to compare dose-response relationships for MPH and AMP and identify dose ranges that balance symptom improvement and adverse event-related discontinuation across benefit-risk preferences. CENTRAL,…

via https://pubmed.ncbi.nlm.nih.gov/41961095/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20260424010911&v=2.19.0.post6+133c1fe